» Articles » PMID: 30906412

Therapeutic Efficiency of an External Chinese Herbal Formula of Mammary Precancerous Lesions by BATMAN-TCM Online Bioinformatics Analysis Tool and Experimental Validation

Overview
Date 2019 Mar 26
PMID 30906412
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Ruyan Neixiao Cream (RYNXC), a patented Chinese herbal formula, was reported to have the effect of treating mammary precancerous disease. In this study, we predicted the potential targets, pathways, and diseases of the ingredients contained in each herbal of RYNXC and constructed an ingredients-targets-diseases network. Then, we analyzed molecular mechanisms of this Chinese herbal formula by MCF-10AT cells and model rats of breast precancerous lesions. BATMAN-TCM prediction showed that ESR1, PGR, PTGS2, EGFR, and Src were mRNA targets of RYNXC. Our results suggested that RYNXC transdermal fluid downregulated ESR1, PGR, PTGS2, EGFR, and Src expression at gene and protein level in MCF-10AT cells. In the rat breast precancerous lesions model, high and low dose RYNXC could also significantly reduce genes and proteins expression of ESR1, PGR, PTGS2, EGFR, and Src. Taken together these data indicate that RYNXC targets multiple molecules responsible for breast precancerous lesion and is an effective Chinese herbal formula. So RYNXC may be a promising external drug for breast precancerous lesions.

Citing Articles

Eugenol inhibits NEAT1 as a ceRNA in pre-cancerous breast lesions.

Liu Y, Zhang G, Ma Y, Ma M, Jiang X Heliyon. 2025; 11(1):e41353.

PMID: 39811361 PMC: 11732537. DOI: 10.1016/j.heliyon.2024.e41353.


Based on the Network Pharmacology to Investigate the Mechanism of Qingjie Fuzheng Granules against Colorectal Cancer.

Fang Y, Yang C, Lu Y, Wei L, Zhao J, Lu L Evid Based Complement Alternat Med. 2022; 2022:7242640.

PMID: 35280511 PMC: 8916896. DOI: 10.1155/2022/7242640.


Based on BATMAN-TCM to Explore the Molecular Mechanism of Xihuang Pill Regulating Immune Function to Treat Breast Precancerous Lesions.

Li D, Fan H, Dong J, Sun C, Su Y, Liu J Breast Cancer (Dove Med Press). 2022; 13:725-742.

PMID: 34992452 PMC: 8711846. DOI: 10.2147/BCTT.S339607.


Network Pharmacology-Based Analysis on the Mechanism of Action of Ephedrae Herba-Cinnamomi Ramulus Couplet Medicines in the Treatment for Psoriasis.

Guo S, Zhou J, Tan C, Shi L, Shi Y, Shi J Med Sci Monit. 2021; 27:e927421.

PMID: 33513128 PMC: 7852043. DOI: 10.12659/MSM.927421.

References
1.
Klapper L, Kirschbaum M, Sela M, Yarden Y . Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res. 1999; 77:25-79. View

2.
Johnson D, Agochiya M, Samejima K, Earnshaw W, Frame M, Wyke J . Regulation of both apoptosis and cell survival by the v-Src oncoprotein. Cell Death Differ. 2000; 7(8):685-96. DOI: 10.1038/sj.cdd.4400700. View

3.
Zhang X, Yee D . Tyrosine kinase signalling in breast cancer: insulin-like growth factors and their receptors in breast cancer. Breast Cancer Res. 2001; 2(3):170-5. PMC: 138771. DOI: 10.1186/bcr50. View

4.
Andrechek E, Muller W . Tyrosine kinase signalling in breast cancer: tyrosine kinase-mediated signal transduction in transgenic mouse models of human breast cancer. Breast Cancer Res. 2001; 2(3):211-6. PMC: 138777. DOI: 10.1186/bcr56. View

5.
Heppner G, Wolman S . MCF-10AT: A Model for Human Breast Cancer Development. Breast J. 2001; 5(2):122-129. DOI: 10.1046/j.1524-4741.1999.00136.x. View